Glaukos Reports Positive Phase 4 Results for iDose® TR Combined with Cataract Surgery
Glaukos Reports Positive Phase 4 Results for iDose TR Combined With Cataract Surgery in Glaucoma Patients Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative treatments…
Seaport Therapeutics Presents New GlyphAgo™ Phase 1 Pharmacokinetic Data at ECNP Congress
Seaport Therapeutics Presents Phase 1 Clinical Data Showing Improved Bioavailability and Reduced Pharmacokinetic Variability for GlyphAgo Seaport Therapeutics, Inc. (Nasdaq: SPTX), a clinical-stage therapeutics company focused on developing innovative medicines…
Ascensia Partners with Sava to Advance Innovative Microsensor Technology
Ascensia Diabetes Care Partners with Sava Technologies to Advance Wearable Microsensor Technology for Glucose Monitoring Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (Tokyo…
FDA Approves Genentech’s Tecentriq Combination for Stage III Colon Cancer Adjuvant Treatment
Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S.…
INBRAIN and MINIGRAPH Develop Robotic Implantation for Graphene Brain-Computer Interfaces
INBRAIN Neuroelectronics Completes MINIGRAPH Project, Advancing Graphene-Based Brain-Computer Interfaces and Robotic Neural Implantation INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing graphene-based brain-computer interface (BCI) therapeutics, has announced the successful completion…
Glaukos Reports Positive Three-Year Epioxa® Results in Keratoconus
Glaukos Reports Positive Three-Year Phase 3 Extension Results for Epioxa in Keratoconus Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative therapies for glaucoma, corneal disorders…
Life Sciences BC Selects Companies and Mentors for Seventh Annual Investor Readiness Program
Life Sciences BC Selects 2027 Investor Readiness Program Cohort to Support Growth of Emerging Life Sciences Companies Life Sciences BC (LSBC) has announced the companies selected to participate in its…
Seaport Therapeutics Doses First Patient in Phase 2a Trial of GlyphAgo™ for Generalized Anxiety Disorder and Sleep Disturbance
PureTech’s Seaport Therapeutics Doses First Patient in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder PureTech Health plc (LSE: PRTC) announced that its Founded Entity, Seaport Therapeutics (Nasdaq: SPTX),…
Pfizer’s TUKYSA Regimen Wins FDA Approval for Front-Line Maintenance in HER2+ Metastatic Breast Cancer
FDA Approves Pfizer’s TUKYSA Regimen for First-Line Maintenance in HER2+ Metastatic Breast Cancer Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination…
Pearl Diagnostics Publishes Clinical Studies Supporting FDA Clearance of MycoMEIA® Aspergillus Assay
PearlDX Publishes Clinical Evidence Supporting FDA-Cleared MycoMEIA Urine Test for Invasive Aspergillosis Pearl Diagnostics, also known as PearlDX, has announced the publication of new clinical studies supporting the U.S. Food…
Medisca and EUROAPI Partner to Expand API Access for Pharmaceutical Compounding
Medisca and EUROAPI Form Strategic Partnership to Expand API Access for Pharmaceutical Compounding Medisca and EUROAPI have entered into a strategic partnership designed to expand access to active pharmaceutical ingredients…
Bridge Neurotech, Butterfly Network Partner on Non-Invasive Brain-Computer Interface
Bridge Neurotech Emerges from Stealth with Non-Invasive Brain-Computer Interface Vision, Partners with Butterfly Network Bridge Neurotech, a company developing a completely non-invasive brain-computer interface (BCI), has emerged from stealth with…